Compare GCTS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | LPCN |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.5M | 61.8M |
| IPO Year | N/A | N/A |
| Metric | GCTS | LPCN |
|---|---|---|
| Price | $1.17 | $8.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 9.0M | 198.7K |
| Earning Date | 11-12-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,893,000.00 | ★ $4,322,693.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,184.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $2.52 |
| 52 Week High | $2.47 | $12.37 |
| Indicator | GCTS | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 54.96 |
| Support Level | $0.96 | $8.80 |
| Resistance Level | $1.84 | $11.11 |
| Average True Range (ATR) | 0.14 | 1.17 |
| MACD | 0.02 | -0.32 |
| Stochastic Oscillator | 23.16 | 22.88 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.